Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Yuko Kitagawa^#¹, Satoru Matsuda^#², Takuji Gotoda³, Ken Kato^{4

5}, Bas Wijnhoven⁶, Florian Lordick⁷, Pradeep Bhandari⁸, Hirofumi Kawakubo², Yasuhiro Kodera⁹, Masanori Terashima¹⁰, Kei Muro¹¹, Hiroya Takeuchi¹², Paul F Mansfield¹³, Yukinori Kurokawa¹⁴, Jimmy So¹⁵, Stefan Paul Mönig¹⁶, Kohei Shitara¹⁷, Sun Young Rha¹⁸, Yelena Janjigian¹⁹, Daisuke Takahari²⁰, Ian Chau²¹, Prateek Sharma²², Jiafu Ji²³, Giovanni de Manzoni²⁴, Magnus Nilsson²⁵, Paulo Kassab²⁶, Wayne L Hofstetter²⁷, Elizabeth Catherine Smyth²⁸, Sylvie Lorenzen²⁹, Yuichiro Doki¹⁴, Simon Law³⁰, Do-Youn Oh³¹, Khek Yu Ho³², Tomoyuki Koike³³, Lin Shen³⁴, Richard van Hillegersberg³⁵, Hisato Kawakami³⁶, Rui-Hua Xu³⁷, Zev Wainberg³⁸, Naohisa Yahagi³⁹, Yeong Yeh Lee⁴⁰, Rajvinder Singh⁴¹, Min-Hee Ryu⁴², Ryu Ishihara⁴³, Zili Xiao⁴⁴, Chika Kusano⁴⁵, Heike Irmgard Grabsch^{46

47}, Hiroki Hara⁴⁸, Ken-Ichi Mukaisho⁴⁹, Tomoki Makino¹⁴, Mitsuro Kanda⁹, Eisuke Booka¹², Sho Suzuki⁵⁰, Waku Hatta³³, Motohiko Kato⁵¹, Akira Maekawa⁵², Akihito Kawazoe¹⁷, Shun Yamamoto^{4

5}, Izuma Nakayama²⁰, Yukiya Narita¹¹, Han-Kwang Yang⁵³, Masahiro Yoshida⁵⁴, Takeshi Sano⁵⁵

Affiliations

¹ Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan. kitagawa@a3.keio.jp.
² Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
³ Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
⁴ Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁵ Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁶ Department of Surgery, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
⁷ Department of Oncology and University Cancer Center Leipzig, Leipzig University Medical Center, Comprehensive Cancer Center Central, Leipzig, Jena, Germany.
⁸ Department of Gastroenterology, Portsmouth University Hospital NHS Trust, Portsmouth, UK.
⁹ Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
¹⁰ Division of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
¹¹ Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
¹² Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
¹³ Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, USA.
¹⁴ Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
¹⁵ Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
¹⁶ Upper-GI-Surgery University Hospital of Geneva, Rue Gabrielle-Perret-Gentil 4, Geneva, Switzerland.
¹⁷ Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
¹⁸ Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
¹⁹ Department of Medicine, Solid Tumor Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
²⁰ Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
²¹ Department of Medicine, Royal Marsden Hospital, London, UK.
²² Division of Gastroenterology, School of Medicine and VA Medical Center, University of Kansas, Kansas, USA.
²³ Department of Gastrointestinal Surgery, Peking University Cancer Hospital, Beijing, China.
²⁴ Department of Surgery, Dentistry, Maternity and Infant, University of Verona, Verona, Italy.
²⁵ Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
²⁶ Gastroesophageal Surgery, Santa Casa of Sao Paulo Medical School, São Paulo, Brazil.
²⁷ Department of Thoracic and Cardiovascular Surgery, University of Texas, MD Anderson Cancer Center, Houston, USA.
²⁸ Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK.
²⁹ Department of Hematology and Oncology, Klinikum Rechts Der Isar Munich, Munich, Germany.
³⁰ Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.
³¹ Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
³² National University of Singapore, Singapore, Singapore.
³³ Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
³⁴ Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China.
³⁵ Department of Upper Gastrointestinal Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
³⁶ Department of Medical Oncology, Faculty of Medicine, Kindai University, Higashiosaka, Japan.
³⁷ Department of Medical Oncology, Sun YAT-Sen University Cancer Center, Guangzhou, China.
³⁸ Gastrointestinal Medical Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
³⁹ Cancer Center, Keio University School of Medicine, Tokyo, Japan.
⁴⁰ School of Medical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
⁴¹ Department of Gastroenterology, Lyell McEwin Hospital, Elizabeth Vale, Australia.
⁴² Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, South Korea.
⁴³ Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
⁴⁴ Digestive Endoscopic Unit, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
⁴⁵ Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
⁴⁶ Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.
⁴⁷ Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
⁴⁸ Gastroenterology, Saitama Cancer Center, Saitama, Japan.
⁴⁹ Education Center for Medicine and Nursing, Shiga University of Medical Science, Otsu, Japan.
⁵⁰ Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan.
⁵¹ Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan.
⁵² Department of Gastroenterology, Osaka Police Hospital, Osaka, Japan.
⁵³ Department of Surgery, Seoul National University, Seoul, Republic of Korea.
⁵⁴ Department of Hepato-Biliary-Pancreatic and Gastrointestinal Surgery, School of Medicine, International University of Health and Welfare, Otawara, Japan.
⁵⁵ Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

^# Contributed equally.

PMID: 38386238
PMCID: PMC11016517
DOI: 10.1007/s10120-023-01457-3

Practice Guideline

Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Yuko Kitagawa et al. Gastric Cancer. 2024 May.

. 2024 May;27(3):401-425.

doi: 10.1007/s10120-023-01457-3. Epub 2024 Feb 22.

Authors

Affiliations

¹ Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan. kitagawa@a3.keio.jp.
² Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
³ Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
⁴ Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁵ Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁶ Department of Surgery, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
⁷ Department of Oncology and University Cancer Center Leipzig, Leipzig University Medical Center, Comprehensive Cancer Center Central, Leipzig, Jena, Germany.
⁸ Department of Gastroenterology, Portsmouth University Hospital NHS Trust, Portsmouth, UK.
⁹ Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
¹⁰ Division of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
¹¹ Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
¹² Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
¹³ Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, USA.
¹⁴ Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
¹⁵ Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
¹⁶ Upper-GI-Surgery University Hospital of Geneva, Rue Gabrielle-Perret-Gentil 4, Geneva, Switzerland.
¹⁷ Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
¹⁸ Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
¹⁹ Department of Medicine, Solid Tumor Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
²⁰ Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
²¹ Department of Medicine, Royal Marsden Hospital, London, UK.
²² Division of Gastroenterology, School of Medicine and VA Medical Center, University of Kansas, Kansas, USA.
²³ Department of Gastrointestinal Surgery, Peking University Cancer Hospital, Beijing, China.
²⁴ Department of Surgery, Dentistry, Maternity and Infant, University of Verona, Verona, Italy.
²⁵ Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
²⁶ Gastroesophageal Surgery, Santa Casa of Sao Paulo Medical School, São Paulo, Brazil.
²⁷ Department of Thoracic and Cardiovascular Surgery, University of Texas, MD Anderson Cancer Center, Houston, USA.
²⁸ Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK.
²⁹ Department of Hematology and Oncology, Klinikum Rechts Der Isar Munich, Munich, Germany.
³⁰ Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.
³¹ Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
³² National University of Singapore, Singapore, Singapore.
³³ Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
³⁴ Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China.
³⁵ Department of Upper Gastrointestinal Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
³⁶ Department of Medical Oncology, Faculty of Medicine, Kindai University, Higashiosaka, Japan.
³⁷ Department of Medical Oncology, Sun YAT-Sen University Cancer Center, Guangzhou, China.
³⁸ Gastrointestinal Medical Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
³⁹ Cancer Center, Keio University School of Medicine, Tokyo, Japan.
⁴⁰ School of Medical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
⁴¹ Department of Gastroenterology, Lyell McEwin Hospital, Elizabeth Vale, Australia.
⁴² Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, South Korea.
⁴³ Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
⁴⁴ Digestive Endoscopic Unit, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
⁴⁵ Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
⁴⁶ Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.
⁴⁷ Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
⁴⁸ Gastroenterology, Saitama Cancer Center, Saitama, Japan.
⁴⁹ Education Center for Medicine and Nursing, Shiga University of Medical Science, Otsu, Japan.
⁵⁰ Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan.
⁵¹ Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan.
⁵² Department of Gastroenterology, Osaka Police Hospital, Osaka, Japan.
⁵³ Department of Surgery, Seoul National University, Seoul, Republic of Korea.
⁵⁴ Department of Hepato-Biliary-Pancreatic and Gastrointestinal Surgery, School of Medicine, International University of Health and Welfare, Otawara, Japan.
⁵⁵ Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

^# Contributed equally.

PMID: 38386238
PMCID: PMC11016517
DOI: 10.1007/s10120-023-01457-3

No abstract available

Keywords: Esophagogastric junction cancer; Guidelines; Multidisciplinary treatment.

PubMed Disclaimer

Conflict of interest statement

EPMs and members of the SR team personally disclosed any conflicts of interests in conformity with the regulations of the journal Gastric Cancer. Yuko Kitagawa received grants or contracts from ASAHI KASEI PHARMA CORPORATION, ONO PHARMACEUTICAL CO., LTD., Otsuka Pharmaceutical Factory Inc., Nippon Covidien Inc., TAIHO PHARMACEUTICAL CO., LTD, CHUGAI PHARMACEUTICAL CO., LTD., KAKEN PHARMACEUTICAL CO., LTD., EA Pharma Co., Ltd., Yakult Honsha Co. Ltd., Otsuka Pharmaceutical Co., Ltd. TSUMURA & CO., Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., TEIJIN PHARMA LIMITED., Cardinal Health., Kowa Company, Ltd., SYSMEX CORPORATION, and Medicaroid Corporation. Yuko Kitagawa received payment or honoraria from ASAHI KASEI PHARMA CORPORATION, AstraZeneca K.K., Ethicon Inc., ONO PHARMACEUTICAL CO., LTD., Otsuka Pharmaceutical Factory, Inc., Olympus Corporation, Cardinal Health K.K., SHIONOGI & CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, CHUGAI PHARMACEUTICAL CO., LTD., Bristol-Myers Squibb K.K., MSD K.K., Smith & Nephew KK, KAKEN PHARMACEUTICAL CO.,LTD., ASKA Pharmaceutical Co., Ltd., MIYARISAN PHARMACEUTICAL CO. LTD., Toray Industries, Inc., DAIICHI SANKYO COMPANY, LIMITED, Chugai Foundation for Innovative Drug Discovery Science, Nippon Kayaku Co., Ltd., EA Pharma Co.,Ltd., Intuitive Surgical G.K., Takeda Pharmaceutical Company Limited, SYSMEX CORPORATION, and TSUMURA & CO. Satoru Matsuda received received payment or honoraria from MSD, BMS, ONO, Olympus, and Novartis. Takuji Gotoda received payment or honoraria from Fujifilm Co., Fujifilm Medical Co., and Olympus Medical Systems Co.. Ken Kato received consulting fee from ONO, Bristol Myers Squibb, Beigene/ Novartis, Astrazeneca, Roche, BAYER, Merck & Co., Merck bio, and Janssen. Ken Kato received payment or honoraria from ONO, and Bristol Myers Squibb. Florian Lordick received grants or contracts from AstraZeneca, BMS, Daiichi Sankyo, Gilead, and MSD. Florian Lordick received consulting fees from Amgen, Astellas, Astra Zeneca, BMS, Daiichi Sankyo, Gilead, MSD, Novartis, and PAGE. Florian Lordick received payment or honoraria from Art tempi, Astra Zeneca, Bayer, Biontech, BMS, Daiichi Sankyo, Eli Lilly, Falk Foundation, Incyte, MedUpdate, Merck, MSD, Novartis, Roche, Servier, and StreamedUp!. Florian Lordick received travel support from BMS and Daiichi Sankyo. Florian Lordick participated on a Data Safety Monitoring Board or Advisory Board of Biontech. Florian Lordick played leadership or fiduciary role in European Society for Medical Oncology and International Gastric Cancer Association. Yasuhiro Kodera received grants or contracts from Chugai Pharma, Daiichi Sankyo, Otsuka, Taiho Pharma, Abbot, Abbvie, Shionogi, Yakult, Lilly Japan, Pfizer, Ono Pharma, Kaken Pharma, Nihon Kayaku, and Bayyer. Yasuhiro Kodera received payment or honoraria Chugai Pharma, Daiichi Sankyo, Taiho Pharma, Abbvie, Yakult, Lilly Japan, Ono Pharma, Bristol Myers Squibb, Amgen, and MSD. Yasuhiro Kodera participated on a Data Safety Monitoring Board or Advisory Board of Daiichi Sankyo. Masanori Terashima received payment or honoraria from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol Myers Squib Japan K.K., Yakult Honsha Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Daiichi Sankyo Ltd., Johnson and Johnson K.K., Medtronic Japan Co., Ltd., Intuitive Japan Inc., and Olympus Co., Ltd.. Kohei Shitara received grants or contracts from Astellas Pharma, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharma, MSD, Amgen, Eisai, PRA Health Sciences, and Syneos Health. Kohei Shitara received consulting fees from Bristol-Myers Squibb, Takeda Pharmaceuticals, Ono Pharmaceutical, Novartis, Daiichi Sankyo, Amgen, Boehringer Ingelheim, MSD, Astellas, Guardant Health Japan, Janssen, AstraZeneca, Zymeworks Biopharmaceuticals Inc, ALX Oncology Inc., and Bayer. Kohei Shitara received payment or honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Janssen, Eli Lilly, Astellas, and AstraZeneca. Sun Young RHA received grants or contracts from AstraZeneca, Ono pharmaceutical, Eisai, Ipsen, Merck Sharp and Dohme, Merck KGaA, Pfizer, BeiGene, Astellas Pharma, AMGEN, ALX Oncology, Zymeworks, Macrogenics, Seagen, Bold therapeutics, MedPacto, ABLBIO, Daiichi Sankyo, Taiho Pharmaceutical, Leap therapeutics, and Arcus Biosciences. Sun Young RHA received consulting fees from LG Biochem and Indivumed. Sun Young RHA received payment or honoraria from MSD, Lilly, Daiichi-Sankyo, and Eisai. Sun Young RHA participated on a Data Safety Monitoring Board or Advisory Board of Amgen. Daisuke Takahari received payment or honoraria from Taiho, Eli-lilly, BMS, Daiichi-Sankyo, and Ono. Paulo Kassab received payment or honoraria from Medtronic. Elizabeth Smyth received grants or contracts from BMS and Astra Zeneca. Elizabeth Smyth received consulting fees from Astra Zeneca, BMS, Daiichi Sankyo, Merck, Astellas, Amgen, Novartis, Pfizer, and Viracta. Elizabeth Smyth received payment or honoraria from Astra Zeneca, BMS, Daiichi Sankyo, Merck, Amgen, Novartis, Viracta, Servier, Beigene, and Roche. Elizabeth Smyth received travel support from Mirati. Elizabeth Smyth participated on a Data Safety Monitoring Board or Advisory Board of Beigene, Zymeworks, and Jazz. Elizabeth Smyth played a leadership or fiduciary role in EORTC Gastric Cancer Taskforce Lead, and UKIOG Trustee. Elizabeth Smyth is supported by the NIHR Biomedical Research Centre at Oxford. The views expressed in this article are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. Sylvie Lorenzen received consulting fees from Amgen, Astellas, Astra Zeneca, BMS, Daiichi Sankyo, MSD, Novartis, Lilly, and Servier. Sylvie Lorenzen received payment or honoraria from Astra Zeneca, BMS, Daiichi Sankyo, Eli Lilly, Incyte, MSD, Novartis, Servier, StreamedUp, and FOMF. Sylvie Lorenzen received travel support from Daiichi Sankyo. Do-Youn Oh received grants for contracts from AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, and Handok. Do-Youn Oh participated on a Data Safety Monitoring Board or Advisory Board of AstraZeneca, Novartis, Genentech/Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA, and MSD. Richard van Hillegersberg received payment or honoraria from Intuitive Surgical. Richard van Hillegersberg played leadership or fiduciary role in ESDE, ISDE, and UGIRA. Hisato Kawakami received grants or contracts from Eisai Co. Ltd.,Taiho Pharmaceutical Co. Ltd, Kobayashi Pharmaceutical. Co., Ltd., Bristol-Myers Squibb Co. Ltd., and Daiichi Sankyo Co. Ltd.. Hisato Kawakami received payment or honoraria from Bristol-Myers Squibb Co. Ltd., Bayer Yakuhin Ltd, Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co. Ltd., Yakult Pharmaceutical Industry, Teijin Pharma Ltd, Taiho Pharmaceutical Co. Ltd, and Otsuka Pharmaceutical Co., Ltd.. Min-Hee Ryu received consulting fees from BMS, Lilly, ONO pharmaceutical, MSD, Novartis, Daiichi Sankyo, AstraZeneca, Sanofi, and Astellas. Min-Hee Ryu received payment or honoraria from BMS, Lilly, ONO pharmaceutical, MSD, Novartis, Daiichi Sankyo, AstraZeneca, Sanofi and Astellas. Sho Suzuki received payment or honoraria from FUJIFILM Corporation, FUJIFILM Medical Co., Ltd., Olympus Corporation, MC Medical, Inc, NEC Corporation, Takeda Pharmaceutical Company, and Mochida Pharmaceutical CO.,LTD.. Yang Han-Kwang received grants or contracts from Intuitive Surgical. Paul Mansfield received stock or stock options from Amgen, and Stryker.

References

1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–406. doi: 10.1016/j.jclinepi.2010.07.015. - DOI - PubMed
1. Rha SY, Wyrwicz LS, Weber PEY, Bai Y, Ryu MH, Lee J, et al. VP1-2023: pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study. Ann Oncol. 2023;34:319–320. doi: 10.1016/j.annonc.2023.01.006. - DOI
1. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655–1668. doi: 10.1016/S0140-6736(23)00620-7. - DOI - PubMed
1. Jaeschke R, Guyatt GH, Dellinger P, Schünemann H, Levy MM, Kunz R, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744. doi: 10.1136/bmj.a744. - DOI - PubMed
1. Han WH, Eom BW, Yoon HM, Reim D, Kim YW, Kim MS, et al. The optimal extent of lymph node dissection in gastroesophageal junctional cancer: retrospective case control study. BMC Cancer. 2019;19:719. doi: 10.1186/s12885-019-5922-8. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Affiliations

Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Authors

Affiliations

Conflict of interest statement

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical